Heart drug trial fails! Novo Nordisk (NVO.US) shares plunge pre-market, increasing concerns over “weight loss drug dependence”
智通财经2026/07/31 13:06Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
JitTong Finance APP has learned that Danish pharmaceutical giant Novo Nordisk (NVO.US) has suffered a significant R&D setback. On Friday, the company announced that its highly anticipated cardiovascular drug under development, ziltivekimab, failed to meet its primary endpoint in a large-scale late-stage clinical trial. The news caused its stock price to plunge more than 10% intraday.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Morgan Stanley: S&P 500 Index Could Fall by Up to 7%
智通财经•2026/09/21 09:11
Euro: Downside risks persist despite ECB hike call – ING
FXStreet•2026/09/21 09:00
Crypto prices
More
Bitcoin
BTC
$83,941.55
+4.56%
Ethereum
ETH
$2,699.67
+4.78%
Tether USDt
USDT
$0.9998
+0.01%
BNB
BNB
$781.68
+4.40%
XRP
XRP
$1.47
+6.90%
USDC
USDC
$0.9998
-0.01%
Solana
SOL
$115.38
+6.70%
TRON
TRX
$0.3441
+0.77%
Zcash
ZEC
$1,516.41
+5.28%
Hyperliquid
HYPE
$95.45
+5.36%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now